physician and nurse time and hospital costs. [7] [8] [9] [10] [11] Furthermore, social costs for patients and caregivers which include travelling, missed work and social activities may be reduced by RM. 12, 13 
Device Management
Lead and device performance monitoring is a physician responsibility and represents a challenge due to the number and complexity of implanted systems and the increased number of advisories during the last 10 years. A strategy based on frequent in-hospital follow-up visits is unsuitable as it places a huge work burden on out-patient clinics. It is also inefficient since malfunctions are rare and likely to be missed when developing suddenly in the interval between visits, with the possibility of causing potentially life-threatening complications. 14 RM allows continuous monitoring, with automatic alerts of battery voltage and impedance, circuit status, charging time, low-and highvoltage lead impedances, sensing and pacing threshold values, external interferences, inappropriate detection of arrhythmias due to noise and double counting or T-wave oversensing (see Figure 1) . Clinical studies have demonstrated that malfunctions are usually asymptomatic and that RM is superior to a standard strategy for early detection. [15] [16] [17] [18] Impact of RM on device longevity is a matter of debate. Concerns 
Disease Management

Atrial Fibrillation
Expected benefits of RM in patients with CIED and atrial fibrillation (AF) are mainly represented by early arrhythmia detection and patient continuous monitoring. Early detection of AF may induce prompt clinical reaction aimed at preventing severe adverse events such as stroke and heart failure. 20 Continuous monitoring allows individual tailoring of patient treatment and continuous updating of therapeutic strategy. AF is very common in CIED patients even in those without any history before implant. Furthermore the majority of events are asymptomatic. 21 CIEDs keep detailed information about AF episodes, including number and duration, arrhythmia recurrences and burden, mean and maximum ventricular rate and intracardiac electrogram strips (see Figure 2) . 22 RM allows continuous access to stored data, and alerts may be programmed for specific events. Early detection of AF by RM has been demonstrated by several trials (for instance five days versus 31 days in the TRUST trial). 5 Clinical evidence for stroke risk reduction by RM is still awaited. Preliminary studies estimated that daily monitoring may reduce the two-year stroke risk by 9-18 % with an absolute reduction of 0.2-0.6 %, compared with conventional inter-visit intervals of 6-12 months. 23, 24 In the Comparative Followup Schedule with Home Monitoring (COMPAS) trial, stroke rate was significantly higher in the control group than in the RM group (3.3 % vs 0.8 %). 8 In the recent Anticoagulation Guided by Remote Rhythm Monitoring in Patients With Implanted Cardioverter-Defibrillator and Resynchronisation Devices (IMPACT) study 25 of oral anticoagulation therapy for AF guided by RM (started in the case of AF detection, stopped in the case of no recurrences), there was no difference in the outcomes of stroke or all-cause mortality between the intervention group and controls. As a matter of fact, 92 % of patients who experienced stroke in the study group were either not anticoagulated at all or had an international normalised ratio (INR) < 2 at the moment of the event.
Considering that several trials have demonstrated no temporal relationship between AF episodes and stroke it should be recommended that, once started for AF, anticoagulation is not discontinued in the absence of device-detected AF. 26 ,27 
Ventricular Arrhythmias
The significant advantage of RM is the prompt evaluation of appropriateness of detection and efficacy of therapy delivered (see The ECOST trial demonstrated that RM significantly reduced the number of actual delivered shocks (-72 %), the number of charged shocks (-76 %) and the rate of inappropriate shocks (-52 %).
19,28
Heart Failure In addition to providing necessary therapies for cardiac arrhythmias and heart failure (HF), modern implantable devices also provide diagnostic information that may be useful in monitoring disease progression and in early detection of deterioration of HF, such as rest and night heart rate, heart rate variability, patient daily Algorithms based on impedance alone showed good sensitivity in HF early detection, on average two weeks in advance, but specificity was poor. [29] [30] [31] [32] The
PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with
Heart Failure) trial demonstrated that patients with a combined HF diagnostic algorithm had a 5.5-fold higher risk of HF event within 30 days. 33 RM strategies have been associated with reduced unplanned device-related or cardiac in-hospital visits and reduced emergency visits for cardiac or device-related events (Evolution of Management
Strategies of Heart Failure Patients with Implantable Defibrillators
[EVOLVO] trial). 34 Studies are ongoing to identify a combined score from device diagnostics with the greatest sensitivity and specificity for predicting HF events. Pressure-based technologies have been introduced to improve HF monitoring. Among them, a wireless implantable pulmonary artery haemodynamic monitoring system, the 
Survival
Evidence is emerging that RM may improve survival. The ALTITUDE database (a large observational retrospective, non-randomised, post-market analysis of real-world data) enrolled about 200,000 patients, 36 of whom 30 % were remotely monitored. In the RM group risk of death was reduced by 50 % both in patients with single/ dual chamber ICDs and in those with CRT defibrillators (CRT-D).
In the prospective randomised IN-TIME (The Influence of Implant-
Based Home Monitoring on the Clinical Management of Heart Failure
Patients with an Impaired Left Ventricular Function) trial, 37 after one year patients in the RM arm, further to a significant improvement in the composite clinical Packer score (mortality plus HF hospitalisations plus New York Heart Association [NYHA] class), showed a 60 % reduction in cardiovascular mortality.
Implementing Remote Monitoring in Daily Practice -The Organisational Model
In spite of the documented benefits, implementing RM in daily clinical practice is challenging and is currently offered only to a minority of potential candidates. 38 Reasons for that include reluctance to accept new technology, concern for legal issues, reimbursement issues, concern for increased work burden in the transition phase, and the need to develop new organisational models. Promising results have been demonstrated by a new model based on 'Primary Nursing' in which each patient is assigned to a nurse responsible for continuity of care. 39 The model is essentially based on a cooperative interaction between the roles of an expert reference nurse and a responsible physician with an agreed Home Guide Registry which enrolled 1,650 patients. 40, 41 Sensitivity of RM in detecting major cardiovascular events was 84 % with a positive predictive value of 97%. RM required a median manpower less than one hour per health personnel per month for every 100 patients.
A centralised 'hub and spoke' model, in which one monitoring centre (hub) screened and filtered daily automatic data in pacemaker and ICD patients from several satellite clinics (spokes), has been suggested to help smaller centres fully utilise RM technology despite limited workforce and low patient numbers that may hamper development of dedicated, experienced, single-centre RM teams. 42 The use of external centralised call centres has been suggested to reduce the work burden of the hospitals and to avoid the need for on-site dedicated expert teams. 43 Personnel at the call centre usually include expert technicians on duty 24 hours a day, seven days a week, with electrophysiologists available on call. Potential advantages of this model may be represented by the 24-hour service and by the possibility of following thousands of patients in a centralised station.
The main limits are represented by the loss of human relationship with the patient and potentially decreased patient compliance and satisfaction. Cost and effectiveness of this strategy could be unfavourable due to call centre costs and to the risk of repetitious alerts and duplication of clinical interventions.
Patient Acceptance and Satisfaction
Several studies have shown high patient satisfaction rates, ease of use and compliance with the use of RM systems, even when manual transmission of the data in non-wireless devices is requested. [44] [45] [46] In spite of some initial concerns, RM has been demonstrated to be easy to use and well accepted even for elderly people and for patients with a low level of education. 47 A few patients do not accept RM mainly due to concerns about technology and about the risk of losing the human contact with nurses and physicians. Patient education is critical to overcoming their concerns. 48 Poor patient compliance may complicate workflow efficiency, mainly because of missed scheduled remote transmissions or duplicate transmissions. Phonecall burden due to patient noncompliance may negatively impact on personnel work load. 49 Automaticity and reliability of the remote technology used is important. In the TRUST trial, no patient assigned to RM crossed over during the study and 98 % elected to retain this follow-up mode on trial conclusion, indicating patient acceptance and confidence in follow-up with this technology. 50 
Legal Issues
RM changes the paradigm of face-to-face visits by gathering electronic data into a data repository that is remote from the health facility, yet readily accessed and shared with various healthcare providers involved in a patient's care or for research or educational purposes.
There are challenges to maintaining the privacy of patient health information and potential issues related to liability for RM-related services. Telemedicine is still a medical act and the patient has to be appropriately informed about the service and must sign an informed The patient has to be informed that currently RM is not an emergency system, but only a tool to improve device surveillance and patient management. Clear instructions have to be given for emergency management. The technology provider is asked to respect the privacy statement and local laws, and to support the hospital centre in all aspects relating to providing patients with a RM service. Hospital duties are mainly to define and make available the facilities needed for RM.
Costs and Reimbursement Issues
Economical analyses have consistently demonstrated CIED RM to be cost effective. 8 This situation is rapidly evolving and soon hopefully homogeneous reimbursement rules will be established in Europe.
Current Guidelines
Since 2006, the Heart Rhythm Society (HRS) 2 recommended that CIED manufacturers developed and implemented wireless and RM technologies to early identify abnormal device behaviour and to reduce under-reporting of device malfunctions. In 2008, the HRS/ European Heart Rhythm Association (EHRA) Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices 1 stated that the majority of in-person follow-up could be replaced by RM. The document suggested to maintain face-to-face visits at predischarge visits, at one-month follow-up and at least once a year. Detail on CIED RM management recommendations has been published by a joint committee of the International Society for Holter and Noninvasive Electrocardiology (ISHNE) and EHRA 4 in 2012 and by some national societies. [57] [58] [59] In the 2013 European Society of Cardiology Guidelines on cardiac pacing and cardiac resynchronisation therapy it was stated that "Device-based RM should be considered in order to provide earlier detection of clinical problems and technical issues" (Recommendation class IIa, level of evidence A). 60 n
Clinical Perspective
• Remote monitoring is rapidly becoming the new standard of care for patients with cardiac implantable electronic devices.
The challenge is to implement remote monitoring in daily practice.
• The key to the success is from one side to invest on human resource (continuous education of personnel and development of the organisational model) and from the other to use technology progress for better interconnectivity and integration of data in the hospital electronic systems.
• Remote reprogramming which is not currently available, but technically feasible, will require great attention to patient safety prior to implementation.
• A clear reimbursement policy is mandatory to dedicate appropriate resource for a remote monitoring service.
